Technical Analysis for MDNAF - Medicenna Therapeutics Corp.

Grade Last Price % Change Price Change
grade D 0.9166 2.19% 0.0196
MDNAF closed up 2.19 percent on Thursday, October 17, 2019, on 1 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical MDNAF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Resistance Bearish 2.19%
Outside Day Range Expansion 2.19%
Wide Bands Range Expansion 2.19%
Oversold Stochastic Weakness 2.19%
Fell Below 20 DMA Bearish 2.19%
Fell Below 50 DMA Bearish 2.19%

Older signals for MDNAF ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and on-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
Medicine RTT Medical Specialties Cancer Clinical Medicine Treatment Of Cancer Immunology Immunotherapy Autoimmune Diseases Solid Tumors Tumor Cancer Treatments Asthma Atopic Dermatitis Immunotherapies Fibrosis Virotherapy Brain Tumor Chimeric Antigen Receptor T Cell
Is MDNAF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 2.2396
52 Week Low 0.5056
Average Volume 16,739
200-Day Moving Average 0.0
50-Day Moving Average 0.955
20-Day Moving Average 1.0105
10-Day Moving Average 0.9317
Average True Range 0.0892
ADX 12.94
+DI 36.3898
-DI 32.714
Chandelier Exit (Long, 3 ATRs ) 1.1324
Chandelier Exit (Short, 3 ATRs ) 1.1276
Upper Bollinger Band 1.2301
Lower Bollinger Band 0.7909
Percent B (%b) 0.29
BandWidth 43.463632
MACD Line -0.0174
MACD Signal Line -0.0059
MACD Histogram -0.0115
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.9166
Resistance 3 (R3) 0.9166 0.9166 0.9166
Resistance 2 (R2) 0.9166 0.9166 0.9166 0.9166
Resistance 1 (R1) 0.9166 0.9166 0.9166 0.9166 0.9166
Pivot Point 0.9166 0.9166 0.9166 0.9166 0.9166
Support 1 (S1) 0.9166 0.9166 0.9166 0.9166 0.9166
Support 2 (S2) 0.9166 0.9166 0.9166 0.9166
Support 3 (S3) 0.9166 0.9166 0.9166
Support 4 (S4) 0.9166